Biomarker-driven Therapy for Melanoma

• Status: Completed
• Trial end date: 2021-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Patients included will undergo biopsy and the molecular analysis will be discussed at the institutional molecular tumor board. The recommandation of the molecular tumor board will be provided to the physician in charge of the patient for final treatment desicion.

The main endpoints are the number of patients with actionable molecular alterations, the number of patients with a treatment recommendation, the number of patients receiving the recommended therapy, overall survival of the patients treated according to recommendations or not. For patients treated according to the recommendations: Response rate and progression free survival at 6 months according to RECIST criteria.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Charite University, Berlin, Germany
• Collaborators: Alacris; Max-Planck Institut

Criteria

Inclusion Criteria:

• histologically proven metastatic melanoma failing standard treatments

• age ≥ 18 years

• Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2

• life expectancy ≥ 24 weeks

• adequate renal, liver, and bone marrow functions

Exclusion Criteria:

• history of cardiac disease or metastatic brain or meningeal tumors